Saturday 17 October 2026
Export IMA’s income statement to Excel — free account
ImageneBio, Inc.
ImageneBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $800,000.00, down 77.1% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 12.5% and free cash flow grew 23.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.04
0.01
+0.25%
Follow IMA
ImageneBio, Inc. (IMA) P/E ratio
ImageneBio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 15 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IBIO iBio, Inc. compare | n/m |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| ANVS Annovis Bio, Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| INMB INmune Bio, Inc. compare | n/m |
| CLNN Clene Inc. compare | n/m |
| SER Serina Therapeutics, Inc. compare | n/m |
| IMA ImageneBio, Inc. | n/m |
| TVGN Tevogen Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)